WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bristol-Myers Squibb

Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

www.bms.com.

Bristol-Myers Squibb RSS Channel

Filters
List of articles in category Bristol-Myers Squibb
Title Published Date
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib 11 March 2020
Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology 04 March 2020
BioMotiv and Bristol-Myers Squibb announce the launch of Anteros Pharmaceuticals 04 February 2020
U.S. Food and Drug Administration accepts for Priority Review Bristol-Myers Squibb's application for Opdivo (nivolumab) plus Yervoy (ipilimumab) in first-line non-small cell lung cancer 17 January 2020
Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, Italy 07 January 2020
Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company 21 November 2019
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals 15 November 2019
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT 31 October 2019
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis 18 October 2019
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement 18 July 2019
Bristol-Myers Squibb provides update on pending merger with Celgene 24 June 2019
Bristol-Myers Squibb announces post-closing leadership team 05 June 2019
Award-winning actor and producer Sterling K. Brown joins Bristol-Myers Squibb in effort to share stories of What It's Like to Live with Cancer Today 16 May 2019
Bristol-Myers Squibb reports first quarter financial results 25 April 2019
Bristol-Myers Squibb shareholders approve Celgene acquisition 12 April 2019
European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma 15 January 2019
Bristol-Myers Squibb to acquire Celgene to create a premier innovative biopharma company 03 January 2019
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance 17 December 2018
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to ReviveMed, Strand Therapeutics 26 November 2018
Bristol-Myers Squibb and Compugen announce clinical collaboration to evaluate therapeutic regimen in advanced solid tumors 11 October 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare
  • Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
  • An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
  • European Commission authorizes COVID-19 vaccine Moderna in Europe

Research & Development

  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system
  • New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
  • Sustained cellular immune dysregulation in individuals recovering from COVID-19
  • How SARS-CoV-2 interacts with cells
  • Neutralizing antibodies protect against severe COVID-19

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Bristol-Myers Squibb
  4. Bristol-Myers Squibb announces changes in its senior management team

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.